Вопросы качества жизни в комплексном обследовании пациентов с системной красной волчанкой
https://doi.org/10.14412/1995-4484-2014-445-450
Аннотация
Системная красная волчанка (СКВ) находится в центре внимания современных исследователей в течение многих лет ввиду хронического прогредиентного течения болезни с зачастую необратимым поражением различных органов и систем, высокого уровня смертности. Несмотря на значительные успехи в диагностике и терапии СКВ, обеспечившие увеличение продолжительности жизни, качество жизни больных остается ниже популяционного уровня. В настоящее время качество жизни наряду с другими параметрами рекомендуется учитывать при проведении комплексного обследования больных СКВ.
Об авторах
C. Т. Абишева
АО «Медицинский университет Астана»,Астана, Казахстан
Россия
Россия
А. А. Сарманова
АО «Медицинский университет Астана», Астана, Казахстан
Россия
Россия
Список литературы
1. Насонов ЕЛ, редактор. Ревматология: Клинические рекомендации. 2-е изд., испр. и доп. Москва: ГЭОТАР-Медиа; 2011. 752 c. [Nasonov EL, editor. Revmatologiya: Klinicheskie rekomendatsii [Rheumatology: Clinical recommendations]. 2nd ed. Moscow: GEOTAR-Media; 2011. 752 p.]
2. Бадокин ВВ, редактор. Ревматология. Клинические лекции. Москва: Литтерра; 2012. 592 с. [Badokin VV, editor. Revmatologiya. Klinicheskie lektsii [Rheumatology. Clinical lectures]. Moscow: Litterra; 2012. 592 p.]
3. Kind P, Williams A. Measuring success in health care – the time has come to do it properly. Health Policy Matter. 2004;(9):1–8.
4. Strand V, Gladman D, Isenberg D, et al. Endpoints: consensus recommendations from OMERACT IV. Outcome Measures in Rheumatology. Lupus. 2000;9(5):322–7. DOI: http://dx.doi.org/10.1191/096120300678828424.
5. Wolfe F, Michaud K, Li T, Katz RS. EQ-5D and SF-36 quality of life measures in systemic lupus erythematosus: comparisons with rheumatoid arthritis, noninflammatory rheumatic disorders, and fibromyalgia. J Rheumatol. 2010;37(2):296–304. DOI: http://dx.doi.org/10.3899/jrheum.090778.
6. McElhone K, Abbott J, Teh LS. A review of health related quality of life in systemic lupus erythematosus. Lupus. 2006;15(10):633–43. DOI: http://dx.doi.org/10.1177/0961203306071710.
7. Stoll T, Gordon C, Seifert B, et al. Consistency and validity of patient administered assessment of quality of life by the MOS SF-36; its association with disease activity and damage in patients with systemic lupus erythematosus. J Rheumatol. 1997;24(8):1608–14.
8. Marx C, Mö rgeli HP, Bü chi S, Stoll T. Are there associations of health status, disease activity and damage in SLE patients? Results of a study of a cohort of a Swiss specialized outpatient clinic. Praxis (Bern 1994). 2007; 96(22):895–9. DOI: http://dx.doi.org/10.1024/1661-8157.96.22.895.
9. Sutcliffe N, Clarke AE, Levinton C, et al. Associates of health status in patients with systemic lupus erythematosus. J Rheumatol. 1999;26(11):2352–6.
10. Dobkin PL, DaCosta D, Dritsa M, et al. Quality of life in systemic lupus erythematosus patients during more or less active disease states: differential contributors to mental and physical health. Arthritis Care Res. 1999;12(6):401–10. DOI: http://dx.doi.org/10.1002/1529-131(199912)12:6%3C401::AIDART8%3E3.0.CO;2-F.
11. Saba J, Quinet RJ, Davis WE, et al. Inverse correlation of each functional status scale of the SF-36 with degree of disease activity in systemic lupus erythematosus (m-SLAM). Joint Bone Spine. 2003;70(5):348–51. DOI: http://dx.doi.org/10.1016/S1297-319X(03)00065-4.
12. Kulczycka L, Sysa-Jedrzejowska A, Robak E. Quality of life and satisfaction with life in SLE patients-the importance of clinical manifestations. Clin Rheumatol. 2010;29(9):991–7. DOI:http://dx.doi.org/10.1007/s10067-010-1509-0.
13. Fortin PR, Abrahamowicz M, Neville C, et al. Impact of disease activity and cumulative damage on the health of lupus patients. Lupus. 1998;7(2):101–7. DOI: http://dx.doi.org/10.1191/096120398678919813.
14. Wilke CT, Jolly M, Block JA, et al. Ability of SF-36 and EQ-5D to discriminate among disease activity levels in lupus. Value in Health. 2007;10(3):15. DOI: http://dx.doi.org/10.1016/S1098- 3015(10)68578-6.
15. Khanna S, Pal H, Pandey RM, Handa R. The relationship between disease activity and quality of life in systemic lupus erythematosus. Rheumatology (Oxford). 2004;43(12):1536–40. DOI: http://dx.doi.org/10.1093/rheumatology/keh376. Epub 2004 Sep 1.
16. Benitha R, Tikly M. Functional disability and health-related quality of life in South Africans with rheumatoid arthritis and systemic lupus erythematosus. Clin Rheumatol. 2007:26(1):24–9. DOI: http://dx.doi.org/10.1007/s10067-006-0215-4.
17. Карпенко ЮЮ. Патология внутренних органов при поздней стадии системной красной волчанки (по данным регионарного регистра). Дисс. …. канд. мед. наук. Воронеж; 2008. [Karpenko YuYu. Patologiya vnutrennikh organov pri pozdnei stadii sistemnoi krasnoi volchanki (po dannym egionarnogo registra). Diss. …. kand. med. nauk [Pathology of an internal at a late stage of a systemic lupus erythematosus (according to the regionarny register); Dr. Diss. (Med. Sci.)].Voronezh; 2008.
18. Асеева ЕА, Амирджанова ВН, Лисицына ТА, Завальская МВ. Качество жизни у больных системной красной волчанкой. Научно-практическая ревматология. 2013;51(3):324–31. [Aseeva EA, Amirdzhanova VN, Lisitsyna TA, Zaval'skaya MV. Quality of life in patients with systemic lupus erythematosus. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practiсе. 2013;51(3):324–31. (In Russ.). DOI: http://dx.doi.org/10.14412/1995-4484-2013-1508.
19. Moldovan I, Katsaros E, Carr FN, et al. The Patient Reported Outcomes in Lupus (PATROL) study: role of depression in healthrelated quality of life in a Southern California lupus cohort. Lupus. 2011;20(12):1285–92. DOI: http://dx.doi.org/10.1177/0961203311412097.
20. Alarcon GS, McGwin G Jr, Uribe A, et al. Systemic Lupus Erythematosus in a Multiethnic Lupus Cohort (LUMINA). XVII. Predictors of self-reported health-related quality of life early in the disease course. Arthritis Rheum. 2004;51(3):465–74. DOI: http://dx.doi.org/10.1002/art.20409.
21. Gladman DD, Urowitz MB, Ong A, et al. Lack of correlation among 3 outcomes describing SLE: disease activity, damage and quality of life. Clin Exp Rheumatol. 1996;14(3):305–8.
22. Thumboo J, Fong KY, Ng T-P, et al. Validation of the MOS SF-36 for quality of life assessment of patients with systemic lupus erythematosus in Singapore. J Rheumatol. 1999;26(1):97–102.
23. Gladman DD, Urowitz MB, Gough J, MacKinnon A. Fibromyalgia is a major contributor to quality of life in lupus. J Rheumatol. 1997;24(11):2145–8.
24. Hanly JG. Disease activity, cumulative damage and quality of life in systemic lupus erythematosus: results of a cross-sectional study. Lupus. 1997;6(3):243–7. DOI: http://dx.doi.org/10.1177/096120339700600305.
25. Gilboe IM, Kvien TK, Husby G. Health status in systemic lupus erythematosus compared to rheumatoid arthritis and healthy controls. J Rheumatol. 1999;26(8):1694–700.
26. Friedman AW, Alarcon GS, McGwin GJr, et al. Systemic lupus erythematosus in three ethnic groups. IV. Factors associated with self-reported functional outcome in a large cohort study. LUMINA Study Group. Lupus in Minority Populations, Nature versus Nurture. Arthritis Care Res. 1999;12(4):256–66. DOI: http://dx.doi.org/10.1002/1529-0131(199908)12:4%3C256::AIDART4% 3E3.0.CO;2-G.
27. Thumboo J, Feng PH, Soh CH, et al. Validation of a Chinese version of the medical outcomes study family and marital functioning measures in patients with SLE. Lupus. 2000;9(9):702–7. DOI: http://dx.doi.org/10.1191/096120300666529212.
28. Doria A, Rinaldi S, Ermani1 M, et al. Health-related quality of life in Italian patients with systemic lupus erythematosus. II. Role of clinical, immunological and psychological determinants. Rheumatology (Oxford). 2004;43(12):1580–6. Epub 2004 Sep 14.
29. Freire EA, Maia IO, Nepomuceno JC, Ciconelli RM. Damage index assessment and quality of life in systemic lupus erythematosus patients (with long-term disease) in Northeastern Brazil. Clin Rheumatol. 2007;26(3):423–8. DOI:http://dx.doi.org/10.1007/s10067-006-0517-6.
30. Kuriya B, Gladman DD, Ibanez D, Urowitz MB. Quality of life over time in patients with systemic lupus erythematosus. Arthritis Care Res. 2008;59(2):181–5. DOI: http://dx.doi.org/10.1002/art.23339.
31. Mok CC, Ho LY, Cheung MY, et al. Effect of disease activity and damage on quality of life in patients with systemic lupus erythematosus: a 2-year prospective study. Scand J Rheumatol. 2009;38(2):121–7. DOI: http://dx.doi.org/10.1080/03009740802415527.
32. Aggarwal R, Wilke CT, Pickard AS, et al. Psychometric properties of the EuroQol-5D and Short Form-6D in patients with systemic lupus erythematosus. J Rheumatol. 2009;36(6):1209–16. DOI:http://dx.doi.org/10.3899/jrheum.081022.
33. Duarte C, Abreu P, Couto M, et al. Health-related quality of life in portuguese SLE patients: an outcome measure independent of disease activity and cumulative damage. Acta Reumatol Port. 2010;35(1):30–5.
34. Gladman D, Urowitz M, Fortin P, et al. Systemic Lupus International Collaborating Clinics conference on assessment of lupus flare and quality of life measures in SLE. Systemic Lupus International Collaborating Clinics Group. J Rheumatol.1996;23(11):1953–5.
35. Strand V, Chu AD. Generic versus Disease-specific Measures of Health-related Quality of Life in Systemic Lupus Erythematosus. J Rheumatol. 2011;38(9):1821–3. DOI: 10.3899/jrheum.110766.
36. Touma Z, Gladman DD, Ibanez D, Urowitz MB. Is there an advantage over SF-36 with a quality of life measure that is specific to systemic lupus erythematosus? J Rheumatol. 2011;38(9):1898–905. DOI: http://dx.doi.org/10.3899/jrheum.110007.
37. Yazdany J. Health-related quality of life measurement in systemic lupus erythematosus: The LupusQoL, SLEQoL, and L-QoL. Arthritis Care Res (Hoboken). 2011;63(Suppl 11):S413–9. DOI: 10.1002/acr.20636.
38. Leong KP, Kong KO, Thong BY, et al. Development and preliminary validation of a systemic lupus erythematosus-specific qualityof-life instrument (SLEQOL). Rheumatology (Oxford). 2005;44(10):1267–76. DOI: http://dx.doi.org/10.1093/rheumatology/keh605.
39. Conti F, Perricone C, Reboldi G, et al. Validation of a disease-specific health-related quality of life measure in adult Italian patients with systemic lupus erythematosus: LupusQoL-IT. Lupus. 2014;23(8):743–51. DOI: http://dx.doi.org/10.1177/0961203314524466.
40. McElhone K, Castelino M, Abbott J, et al. The LupusQoL and associations with demographics and clinical measurements in patients with systemic lupus erythematosus. J Rheumatol. 2010;37(11):2273–9. DOI: http://dx.doi.org/10.3899/jrheum.091277.
41. Garcia-Carrasco M, Mendoza-Pinto C, Cardiel MH, et al. Health related quality of life in Mexican women with systemic lupus erythematosus: a descriptive study using SF-36 and LupusQoL. Lupus. 2012;21(11):1219–24. DOI: http://dx.doi.org/10.1177/0961203312456749.
42. Castelino M, Abbott J, McElhone K, Teh LS. Comparison of the psychometric properties of health-related quality of life measures used in adults with systemic lupus erythematosus: a review of the literature. Rheumatology (Oxford). 2013;52(4):684–96. DOI: http://dx.doi.org/10.1093/rheumatology/kes370.
43. Stoll T, Stucki G, Malik J, et al. Association of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index with measures of disease activity and health status in patients with systemic lupus erythematosus. J Rheumatol. 1997;24(2):309–13.
44. Medeiros MM, Menezes AP, Silveira VA, et al. Health-related quality of life in patients with systemic lupus erythematosus and its relationship with cyclophosphamide pulse therapy. Eur J Intern Med. 2008;19(2):122–8. DOI: http://dx.doi.org/10.1016/j.ejim.2007.06.012.
45. Hanly JG, Urowitz MB, Jackson D, et al. Systemic Lupus International Collaborating Clinics (SLICC). SF-36 summary and subscale scores are reliable outcomes of neuropsychiatric events in systemic lupus erythematosus. Ann Rheum Dis. 2011;70(6):961–7. DOI: http://dx.doi.org/10.1136/ard.2010.138792.
46. Appenzeller S, Clarke AE, Panopalis P, et al. The relationship between renal activity and quality of life in systemic lupus erythematosus. J Rheumatol. 2009;36(5):947–52. DOI:http://dx.doi.org/10.3899/jrheum.080822.
47. Чугунная СМ. Патология легких у больных системной красной волчанкой (клинические, инструментальные и биохимические аспекты). Дисс. … канд. мед. наук, Москва; 2005. [Chugunnaya SM. Patologiya legkikh u bol'nykh sistemnoi krasnoi volchankoi (klinicheskie, instrumental'nye i biokhimicheskie aspekty). Diss. … kand. med. nauk [Pathology of lungs at patients with a systemic lupus erythematosus (clinical, tool and biochemical aspects): Dr. Diss. (Med. Sci.)]. Moscow; 2005.]
48. Pettersson S, Lovgren M, Eriksson LE, et al. An exploration of patient-reported symptoms in systemic lupus erythematosus and the relationship to health-related quality of life. Scand J Rheumatol. 2012;41(5):383–90. DOI: http://dx.doi.org/10.3109/03009742.2012.677857.
49. Федоренко ДА. Синдром генерализованной слабости и его влияние на параметры качества жизни у больных некоторыми системными заболеваниями соединительной ткани. Дисс. … канд. мед. наук. Санкт-Петербург; 2004. [Fedorenko DA. Sindrom generalizovannoi slabosti i ego vliyanie na parametry kachestva zhizni u bol'nykh nekotorymi sistemnymi zabolevaniyami soedinitel'noi tkani. Diss. … kand. med. nauk [Syndrome of generalized weakness and its influence on parameters of quality of life at patients with some system diseases of connecting fabric: Dr. Diss. (Med. Sci.)]. Sankt-Peterburg; 2004.]
50. Choi ST, Kang JI, Park IH, et al. Subscale analysis of quality of life in patients with systemic lupus erythematosus: association with depression, fatigue, disease activity and damage. Clin Exp Rheumatol. 2012;30(5):665–72.
51. Navarrete-Navarrete N, Peralta-Ramirez MI, Sabio JM, et al. Quality-of-life predictor factors in patients with SLE and their modification after cognitive behavioural therapy. Lupus. 2010;19(14):1632–9. DOI: 10.1177/0961203310378413. Epub 2010 Sep 14.
52. Mak A, Tang CS, Ho RC. Serum tumour necrosis factor-alpha is associated with poor health-related quality of life and depressive symptoms in patients with systemic lupus erythematosus. Lupus. 2013;22(3):254–61. DOI: http://dx.doi.org/10.1177/0961203312471872.
53. Daleboudt GM, Berger SP, Broadbent E, Kaptein AA. Healthrelated quality of life in patients with systemic lupus erythematosus and proliferative lupus nephritis. Psychol Health Med. 2011;16(4):393–404. DOI: 10.1080/13548506.2011.554566.
54. Urowitz M, Gladman DD, Ibanez D, et al. Changes in quality of life in the first 5 years of disease in a multicentre cohort of patients with systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2014 Feb 4. DOI: 10.1002/acr.22299.
55. Thumboo J, Strand V. Health-related quality of life in patients with systemic lupus erythematosus: an update. Ann Acad Med Singapore. 2007;36(2):115–22.
56. Jolly M, Sandler DS, Sequeira W, Block JA. Hydroxy-chloroquine use and disease specific health related quality of life in systemic lupus erythematosus. Arthritis Rheum. 2009;60(10):293.
57. Berger SP, Broadbent E, Kaptein AA. Health-related quality of life in patients with systemic lupus erythematosus and proliferative lupus nephritis. Psychology Health Med. 2011;16(4):393–404. DOI: 10.1080/13548506.2011.554566.
58. Dussan KB, Magder L, Brodsky RA, et al. High dose cyclophosphamide performs better than monthly dose cyclophosphamide in quality of life measures. Lupus. 2008;17(12):1079–85. DOI: http://dx.doi.org/10.1177/0961203308093828.
59. Grootscholten C, Snoek FJ, Bijl M, et al. Health-related quality of life and treatment burden in patients with proliferative lupus nephritis treated with cyclophosphamide or azathioprine/ ethylprednisolone in a randomized controlled trial. J Rheumatol. 2007;34(8):1699–707.
60. Medeiros MM, Menezes AP, Silveira VA, et al. Health-related quality of life in patients with systemic lupus erythematosus and its relationship with cyclophosphamide pulse therapy. Eur J Intern Med. 2008 Mar;19(2):122–8. DOI: http://dx.doi.org/10.1016/j.ejim.2007.06.012.
61. Tse KC, Tang CS, Lio WI, et al. Quality of life comparison between corticosteroid -and-mycofenolate mofetil and corticosteroid -and-oral cyclophosphamide in the treatment of severe lupus nephritis. Lupus. 2006;15(6):371–9. DOI: http://dx.doi.org/10.1191/0961203306lu2307xx.
62. Wilson EC, Jayne DR, Dellow D, Fordham RJ. The cost-effectiveness of mycophenolate mofetil as first line therapy in active lupus nephritis. Rheumatology (Oxford). 2007;46(7);1096–101. DOI: http://dx.doi.org/10.1093/rheumatology/kem054. Epub 2007 Apr 4.
63. Navarrete-Navarrete N, Peralta-Ramхirez MI, Sabio JM, et al. Quality-of-life predictor factors in patients with SLE and their modification after cognitive behavioural therapy. Lupus. 2010;19(14):1632–9. DOI: 10.1177/0961203310378413. Epub 2010 Sep 14.
Рецензия
Для цитирования:
Абишева C.Т., Сарманова А.А. Вопросы качества жизни в комплексном обследовании пациентов с системной красной волчанкой. Научно-практическая ревматология. 2014;52(4):445-450. https://doi.org/10.14412/1995-4484-2014-445-450
For citation:
Abisheva S.T., Sarmanova A.A. QUALITY-OF-LIFE ISSUES IN THE COMPREHENSIVE EXAMINATION OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS. Rheumatology Science and Practice. 2014;52(4):445-450. (In Russ.) https://doi.org/10.14412/1995-4484-2014-445-450
Просмотров:
1730
Послать статью по эл. почте 